25 XP   0   0   10

GT Biopharma Inc
Buy, Hold or Sell?

Let's analyse GT Biopharma Inc together

PenkeI guess you are interested in GT Biopharma Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of GT Biopharma Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about GT Biopharma Inc

I send you an email if I find something interesting about GT Biopharma Inc.

Quick analysis of GT Biopharma Inc (30 sec.)










What can you expect buying and holding a share of GT Biopharma Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$5.41
Expected worth in 1 year
$2.33
How sure are you?
35.0%

+ What do you gain per year?

Total Gains per Share
$-3.08
Return On Investment
-84.5%

For what price can you sell your share?

Current Price per Share
$3.65
Expected price per share
$3.52 - $5.21
How sure are you?
50%

1. Valuation of GT Biopharma Inc (5 min.)




Live pricePrice per Share (EOD)

$3.65

Intrinsic Value Per Share

$-77.82 - $-42.11

Total Value Per Share

$-72.41 - $-36.70

2. Growth of GT Biopharma Inc (5 min.)




Is GT Biopharma Inc growing?

Current yearPrevious yearGrowGrow %
How rich?$7.4m$15.2m-$4.6m-44.0%

How much money is GT Biopharma Inc making?

Current yearPrevious yearGrowGrow %
Making money-$2.8m-$5.1m$2.2m81.1%
Net Profit Margin0.0%0.0%--

How much money comes from the company's main activities?

3. Financial Health of GT Biopharma Inc (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#704 / 1010

Most Revenue
#966 / 1010

Most Profit
#345 / 1010

Most Efficient
#408 / 1010

What can you expect buying and holding a share of GT Biopharma Inc? (5 min.)

Welcome investor! GT Biopharma Inc's management wants to use your money to grow the business. In return you get a share of GT Biopharma Inc.

What can you expect buying and holding a share of GT Biopharma Inc?

First you should know what it really means to hold a share of GT Biopharma Inc. And how you can make/lose money.

Speculation

The Price per Share of GT Biopharma Inc is $3.65. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of GT Biopharma Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in GT Biopharma Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $5.41. Based on the TTM, the Book Value Change Per Share is $-0.77 per quarter. Based on the YOY, the Book Value Change Per Share is $1.95 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of GT Biopharma Inc.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-2.15-58.8%-2.04-55.9%-1.11-30.3%-1.64-44.8%-6.00-164.3%
Usd Book Value Change Per Share-1.83-50.2%-0.77-21.1%1.9553.4%0.082.2%0.256.9%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-1.83-50.2%-0.77-21.1%1.9553.4%0.082.2%0.256.9%
Usd Price Per Share0.26-0.34-2.13-2.18-1.60-
Price to Earnings Ratio-0.03--0.04--3.55--2.67--1.36-
Price-to-Total Gains Ratio-0.14--0.02-12.37--3.13--0.87-
Price to Book Ratio0.05-0.04-3.72-1.83-0.93-
Price-to-Total Gains Ratio-0.14--0.02-12.37--3.13--0.87-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share3.65
Number of shares273
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.770.08
Usd Total Gains Per Share-0.770.08
Gains per Quarter (273 shares)-210.4922.27
Gains per Year (273 shares)-841.9889.09
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-842-85208979
20-1684-16940178168
30-2526-25360267257
40-3368-33780356346
50-4210-42200445435
60-5052-50620535524
70-5894-59040624613
80-6736-67460713702
90-7578-75880802791
100-8420-84300891880

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%3.037.00.07.5%17.0119.03.012.2%
Book Value Change Per Share1.03.00.025.0%4.08.00.033.3%6.014.00.030.0%14.026.00.035.0%44.088.07.031.7%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.040.00.0%0.00.0139.00.0%
Total Gains per Share1.03.00.025.0%4.08.00.033.3%6.014.00.030.0%14.026.00.035.0%44.088.07.031.7%

Fundamentals of GT Biopharma Inc

About GT Biopharma Inc

GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies. The company is developing GTB-3650, which is in preclinical studies that target CD33 on the surface of myeloid leukemias; and GTB-5550 that is in preclinical studies for treating patients with B7-H3 positive solid tumors. GT Biopharma, Inc. has a co-development partnership agreement with Altor BioScience Corporation for the clinical development of a 161533 TriKE fusion protein for cancer therapies; and a license agreement with the Regents of the University of Minnesota to develop and commercialize cancer therapies using TriKE technology. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in Brisbane, California.

Fundamental data was last updated by Penke on 2024-04-11 10:25:03.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is cheap.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of GT Biopharma Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit GT Biopharma Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare GT Biopharma Inc to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that $0.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of GT Biopharma Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-5,436.1%+5,436.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--200.1%+200.1%
TTM--216.8%+216.8%
YOY--288.3%+288.3%
5Y--449.1%+449.1%
10Y-5,436.1%-605.5%-4,830.6%
1.1.2. Return on Assets

Shows how efficient GT Biopharma Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare GT Biopharma Inc to the Biotechnology industry mean.
  • -21.0% Return on Assets means that GT Biopharma Inc generated $-0.21 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of GT Biopharma Inc:

  • The MRQ is -21.0%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -16.6%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-21.0%TTM-16.6%-4.4%
TTM-16.6%YOY-24.0%+7.4%
TTM-16.6%5Y-13,630.7%+13,614.1%
5Y-13,630.7%10Y-6,988.0%-6,642.7%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-21.0%-13.3%-7.7%
TTM-16.6%-12.8%-3.8%
YOY-24.0%-11.7%-12.3%
5Y-13,630.7%-13.9%-13,616.8%
10Y-6,988.0%-15.7%-6,972.3%
1.1.3. Return on Equity

Shows how efficient GT Biopharma Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare GT Biopharma Inc to the Biotechnology industry mean.
  • -39.6% Return on Equity means GT Biopharma Inc generated $-0.40 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of GT Biopharma Inc:

  • The MRQ is -39.6%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -27.7%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-39.6%TTM-27.7%-12.0%
TTM-27.7%YOY-34.3%+6.7%
TTM-27.7%5Y-21.8%-5.9%
5Y-21.8%10Y-59.2%+37.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-39.6%-16.9%-22.7%
TTM-27.7%-16.1%-11.6%
YOY-34.3%-15.1%-19.2%
5Y-21.8%-19.3%-2.5%
10Y-59.2%-20.2%-39.0%

1.2. Operating Efficiency of GT Biopharma Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient GT Biopharma Inc is operating .

  • Measures how much profit GT Biopharma Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare GT Biopharma Inc to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of GT Biopharma Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y1,181.0%-1,181.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--296.2%+296.2%
TTM--232.5%+232.5%
YOY--298.2%+298.2%
5Y--492.1%+492.1%
10Y1,181.0%-632.4%+1,813.4%
1.2.2. Operating Ratio

Measures how efficient GT Biopharma Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of GT Biopharma Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y-0.000
5Y-10Y40.198-40.198
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-3.231-3.231
TTM-3.310-3.310
YOY-3.890-3.890
5Y-5.739-5.739
10Y40.1987.876+32.322

1.3. Liquidity of GT Biopharma Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if GT Biopharma Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 2.12 means the company has $2.12 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of GT Biopharma Inc:

  • The MRQ is 2.119. The company is able to pay all its short-term debts. +1
  • The TTM is 3.471. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ2.119TTM3.471-1.352
TTM3.471YOY3.288+0.184
TTM3.4715Y2.591+0.880
5Y2.59110Y1.349+1.242
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.1193.890-1.771
TTM3.4714.173-0.702
YOY3.2885.344-2.056
5Y2.5916.126-3.535
10Y1.3496.448-5.099
1.3.2. Quick Ratio

Measures if GT Biopharma Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare GT Biopharma Inc to the Biotechnology industry mean.
  • A Quick Ratio of 4.05 means the company can pay off $4.05 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of GT Biopharma Inc:

  • The MRQ is 4.050. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 6.484. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ4.050TTM6.484-2.434
TTM6.484YOY5.767+0.717
TTM6.4845Y4.120+2.364
5Y4.12010Y2.112+2.007
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ4.0503.514+0.536
TTM6.4843.998+2.486
YOY5.7675.380+0.387
5Y4.1206.105-1.985
10Y2.1126.404-4.292

1.4. Solvency of GT Biopharma Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of GT Biopharma Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare GT Biopharma Inc to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.47 means that GT Biopharma Inc assets are financed with 47.0% credit (debt) and the remaining percentage (100% - 47.0%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of GT Biopharma Inc:

  • The MRQ is 0.470. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.388. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.470TTM0.388+0.082
TTM0.388YOY0.314+0.074
TTM0.3885Y11.626-11.238
5Y11.62610Y109.534-97.909
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.4700.339+0.131
TTM0.3880.336+0.052
YOY0.3140.271+0.043
5Y11.6260.366+11.260
10Y109.5340.389+109.145
1.4.2. Debt to Equity Ratio

Measures if GT Biopharma Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare GT Biopharma Inc to the Biotechnology industry mean.
  • A Debt to Equity ratio of 88.7% means that company has $0.89 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of GT Biopharma Inc:

  • The MRQ is 0.887. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.646. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.887TTM0.646+0.242
TTM0.646YOY0.464+0.182
TTM0.6465Y0.424+0.222
5Y0.42410Y0.722-0.298
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.8870.388+0.499
TTM0.6460.402+0.244
YOY0.4640.335+0.129
5Y0.4240.426-0.002
10Y0.7220.461+0.261

2. Market Valuation of GT Biopharma Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings GT Biopharma Inc generates.

  • Above 15 is considered overpriced but always compare GT Biopharma Inc to the Biotechnology industry mean.
  • A PE ratio of -0.03 means the investor is paying $-0.03 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of GT Biopharma Inc:

  • The EOD is -0.425. Based on the earnings, the company is expensive. -2
  • The MRQ is -0.030. Based on the earnings, the company is expensive. -2
  • The TTM is -0.042. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.425MRQ-0.030-0.396
MRQ-0.030TTM-0.042+0.012
TTM-0.042YOY-3.550+3.508
TTM-0.0425Y-2.672+2.630
5Y-2.67210Y-1.360-1.312
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.425-2.264+1.839
MRQ-0.030-2.629+2.599
TTM-0.042-2.680+2.638
YOY-3.550-4.145+0.595
5Y-2.672-6.257+3.585
10Y-1.360-6.254+4.894
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of GT Biopharma Inc:

  • The EOD is -0.615. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -0.043. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -0.052. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.615MRQ-0.043-0.572
MRQ-0.043TTM-0.052+0.009
TTM-0.052YOY-4.417+4.366
TTM-0.0525Y-4.218+4.166
5Y-4.21810Y-2.284-1.934
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.615-2.973+2.358
MRQ-0.043-3.333+3.290
TTM-0.052-3.553+3.501
YOY-4.417-5.605+1.188
5Y-4.218-8.376+4.158
10Y-2.284-8.865+6.581
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of GT Biopharma Inc is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 0.05 means the investor is paying $0.05 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of GT Biopharma Inc:

  • The EOD is 0.674. Based on the equity, the company is cheap. +2
  • The MRQ is 0.047. Based on the equity, the company is cheap. +2
  • The TTM is 0.044. Based on the equity, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD0.674MRQ0.047+0.627
MRQ0.047TTM0.044+0.003
TTM0.044YOY3.719-3.675
TTM0.0445Y1.833-1.789
5Y1.83310Y0.931+0.902
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD0.6741.896-1.222
MRQ0.0472.115-2.068
TTM0.0442.093-2.049
YOY3.7192.884+0.835
5Y1.8333.542-1.709
10Y0.9313.916-2.985
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of GT Biopharma Inc.

3.1. Institutions holding GT Biopharma Inc

Institutions are holding 13.456% of the shares of GT Biopharma Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-09-30Vanguard Group Inc2.624901087234-12120-1.1025
2023-09-30Bank of Montreal1.43950.000159624000
2023-09-30BMO Capital Markets Corp.1.43950.000159624000
2023-09-30Geode Capital Management, LLC0.8144033731511387150.9618
2023-09-30BlackRock Inc0.73410304041-763-0.2503
2023-09-30Wells Fargo & Co0.7260300697200103198.9214
2023-12-31Bank of New York Mellon Corp0.229909523900
2023-09-30Atria Wealth Solutions, Inc.0.21420.0003887202000029.1036
2023-09-30Millennium Management LLC0.2125088009-146848-62.5266
2023-09-30State Street Corporation0.193107997600
2023-09-30Renaissance Technologies Corp0.161066700-25481-27.6424
2023-09-30Northern Trust Corp0.078103234700
2023-09-30TWO SIGMA SECURITIES, LLC0.07470.000130959309590
2023-09-30Tower Research Capital LLC0.04870.0002201583351.69
2023-09-30Moss Adams Wealth Advisors LLC0.04830.00172000010000100
2023-09-30Goldman Sachs Group Inc0.0252010424-76-0.7238
2023-09-30Commonwealth Equity Services Inc0.024401011000
2023-12-31Welch Group, LLC0.02410.00011000000
2023-09-30UBS Group AG0.0211087505717188.4932
2023-09-30Morgan Stanley - Brokerage Accounts0.01950807800
Total 9.15320.00263791237+195697+5.2%

3.2. Funds holding GT Biopharma Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-01-31Fidelity Extended Market Index0.55280.000122898700
2023-09-30BlackRock Extended Mkt Composite0.09630.00013987400
2023-12-31BlackRock Extended Equity Market K0.0840.000134787-70-0.2008
2024-01-31Fidelity Series Total Market Index0.083503456600
2024-01-31Fidelity Nasdaq Composite Index0.074103067300
2024-01-31Fidelity Total Market Index0.071902978600
2023-12-31NT Ext Equity Mkt Idx Fd - NL0.04380.00011814200
2023-12-31NT Ext Equity Mkt Idx Fd - DC - NL - T20.03520.000114571270.1856
2024-01-31Spartan Total Market Index Pool E0.029801235000
2023-12-31NT Ext Equity Mkt Idx Fd - L0.02820.00011167200
2023-12-31Northern Trust Extended Eq Market Idx0.02820.00011167200
2024-02-29Vanguard Total Stock Mkt Idx Inv0.8085011163-537-4.5897
2024-02-29Vanguard Institutional Extnd Mkt Idx Tr0.760801050410.0095
2023-12-31BlackRock U.S. Equity Market F0.02209101160.1761
2023-12-31SSgA U.S. Extended Market Index Class I0.01960.0001810000
2023-10-31Vanguard Instl Ttl Stck Mkt Idx Tr0.015806559-797941-99.1847
2023-12-31Extended Equity Market Fund M0.01040.000143012055.0049
2023-12-31Northern Trust Wilshire 50000.00570236300
2023-12-31NT US Market Cap Idx Fd - L0.00570236300
2023-12-31SSgA U.S. Total Market Index Strategy0.005602336-54-2.2594
Total 2.78190.0009523870-798353-152.4%

3.3. Insider Transactions

Insiders are holding 10.417% of the shares of GT Biopharma Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2023-04-11Michael Martin BreenBUY166615

4. Summary

4.1. Key Performance Indicators

The key performance indicators of GT Biopharma Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---1.832-0.771-58%1.950-194%0.082-2345%0.250-833%
Book Value Per Share--5.4157.659-29%2.512+116%0.991+447%6.298-14%
Current Ratio--2.1193.471-39%3.288-36%2.591-18%1.349+57%
Debt To Asset Ratio--0.4700.388+21%0.314+50%11.626-96%109.534-100%
Debt To Equity Ratio--0.8870.646+37%0.464+91%0.424+109%0.722+23%
Dividend Per Share----0%-0%-0%-0%
Eps---2.145-2.042-5%-1.108-48%-1.636-24%-5.997+180%
Free Cash Flow Per Share---1.483-1.603+8%-0.864-42%-0.654-56%-0.628-58%
Free Cash Flow To Equity Per Share---1.483-0.395-73%-0.868-41%-0.183-88%0.036-4199%
Gross Profit Margin--1.0001.0000%1.049-5%1.010-1%1.0050%
Intrinsic Value_10Y_max---42.111--------
Intrinsic Value_10Y_min---77.825--------
Intrinsic Value_1Y_max---2.761--------
Intrinsic Value_1Y_min---4.218--------
Intrinsic Value_3Y_max---9.409--------
Intrinsic Value_3Y_min---15.849--------
Intrinsic Value_5Y_max---17.396--------
Intrinsic Value_5Y_min---30.872--------
Market Cap5039299.500+93%352064.730468759.421-25%60853264.578-99%59493373.188-99%30873220.362-99%
Net Profit Margin----0%-0%-0%-54.3610%
Operating Margin----0%-0%-0%11.810-100%
Operating Ratio----0%-0%-0%40.198-100%
Pb Ratio0.674+93%0.0470.044+8%3.719-99%1.833-97%0.931-95%
Pe Ratio-0.425-1331%-0.030-0.042+40%-3.550+11847%-2.672+8892%-1.360+4478%
Price Per Share3.650+93%0.2550.340-25%2.129-88%2.184-88%1.601-84%
Price To Free Cash Flow Ratio-0.615-1331%-0.043-0.052+20%-4.417+10173%-4.218+9709%-2.284+5211%
Price To Total Gains Ratio-1.993-1331%-0.139-0.022-84%12.374-101%-3.135+2152%-0.873+527%
Quick Ratio--4.0506.484-38%5.767-30%4.120-2%2.112+92%
Return On Assets---0.210-0.166-21%-0.240+14%-136.307+64828%-69.880+33186%
Return On Equity---0.396-0.277-30%-0.343-13%-0.218-45%-0.592+49%
Total Gains Per Share---1.832-0.771-58%1.950-194%0.082-2345%0.250-833%
Usd Book Value--7476000.00010574250.000-29%15229250.000-51%3356150.000+123%19990025.000-63%
Usd Book Value Change Per Share---1.832-0.771-58%1.950-194%0.082-2345%0.250-833%
Usd Book Value Per Share--5.4157.659-29%2.512+116%0.991+447%6.298-14%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---2.145-2.042-5%-1.108-48%-1.636-24%-5.997+180%
Usd Free Cash Flow---2047000.000-2213000.000+8%-3804250.000+86%-2441950.000+19%-1807125.000-12%
Usd Free Cash Flow Per Share---1.483-1.603+8%-0.864-42%-0.654-56%-0.628-58%
Usd Free Cash Flow To Equity Per Share---1.483-0.395-73%-0.868-41%-0.183-88%0.036-4199%
Usd Market Cap5039299.500+93%352064.730468759.421-25%60853264.578-99%59493373.188-99%30873220.362-99%
Usd Price Per Share3.650+93%0.2550.340-25%2.129-88%2.184-88%1.601-84%
Usd Profit---2962000.000-2819250.000-5%-5105500.000+72%-7095550.000+140%-13944625.000+371%
Usd Revenue----0%-0%-0%7875.000-100%
Usd Total Gains Per Share---1.832-0.771-58%1.950-194%0.082-2345%0.250-833%
 EOD+5 -3MRQTTM+4 -25YOY+7 -235Y+10 -2010Y+12 -21

4.2. Fundamental Score

Let's check the fundamental score of GT Biopharma Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-0.425
Price to Book Ratio (EOD)Between0-10.674
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than14.050
Current Ratio (MRQ)Greater than12.119
Debt to Asset Ratio (MRQ)Less than10.470
Debt to Equity Ratio (MRQ)Less than10.887
Return on Equity (MRQ)Greater than0.15-0.396
Return on Assets (MRQ)Greater than0.05-0.210
Total5/10 (50.0%)

4.3. Technical Score

Let's check the technical score of GT Biopharma Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5039.178
Ma 20Greater thanMa 504.032
Ma 50Greater thanMa 1004.201
Ma 100Greater thanMa 2005.468
OpenGreater thanClose3.650
Total0/5 (0.0%)



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets14,109
Total Liabilities6,633
Total Stockholder Equity7,476
 As reported
Total Liabilities 6,633
Total Stockholder Equity+ 7,476
Total Assets = 14,109

Assets

Total Assets14,109
Total Current Assets14,056
Long-term Assets53
Total Current Assets
Cash And Cash Equivalents 1,079
Short-term Investments 12,893
Other Current Assets 84
Total Current Assets  (as reported)14,056
Total Current Assets  (calculated)14,056
+/-0
Long-term Assets
Property Plant Equipment 53
Long-term Assets  (as reported)53
Long-term Assets  (calculated)53
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities6,633
Long-term Liabilities0
Total Stockholder Equity7,476
Total Current Liabilities
Short-term Debt 58
Accounts payable 4,328
Other Current Liabilities 2,247
Total Current Liabilities  (as reported)6,633
Total Current Liabilities  (calculated)6,633
+/-0
Long-term Liabilities
Long-term Liabilities  (as reported)0
Long-term Liabilities  (calculated)0
+/-0
Total Stockholder Equity
Common Stock1
Retained Earnings -682,065
Other Stockholders Equity 689,540
Total Stockholder Equity (as reported)7,476
Total Stockholder Equity (calculated)7,476
+/-0
Other
Capital Stock2
Cash and Short Term Investments 13,972
Common Stock Shares Outstanding 1,381
Liabilities and Stockholders Equity 14,109
Net Debt -1,021
Net Invested Capital 7,475
Net Working Capital 7,423
Property Plant and Equipment Gross 53
Short Long Term Debt Total 58



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-312009-12-312009-09-302009-06-302009-03-312008-12-312008-09-302008-06-302008-03-312007-12-312007-09-302007-06-302007-03-312006-12-312006-09-302006-06-302006-03-312005-12-312005-09-302005-06-302005-03-312004-12-312004-09-302004-06-302004-03-312003-12-312003-09-302003-06-302003-03-312002-12-312002-09-302002-06-302002-03-312001-12-312001-09-302001-06-302001-03-312000-12-312000-09-302000-06-302000-03-311999-12-311999-09-301999-06-301999-03-311998-12-311998-09-301998-06-301998-03-311997-12-311997-09-301997-06-301997-03-311996-12-311996-09-301996-06-301996-03-311995-12-311995-09-301995-06-301995-03-311994-12-311994-09-301994-06-301994-03-311993-12-311993-09-301993-06-301993-03-311992-12-311992-09-301992-06-301992-03-311991-12-311991-09-301991-06-301991-03-311990-12-311990-09-301990-06-301990-03-311989-12-311989-09-301989-06-301989-03-311988-12-311988-09-301988-06-301988-03-311987-12-311987-09-301987-06-301987-03-311986-12-311986-09-301986-06-301986-03-311985-12-311985-09-30
> Total Assets 
0
3,200
0
0
0
3,300
0
0
0
3,300
0
0
0
3,500
0
4,200
4,300
4,400
4,900
5,100
4,800
5,000
4,900
5,000
5,300
4,800
4,500
4,800
4,800
4,900
4,900
3,500
3,500
3,100
3,100
3,700
12,100
11,200
11,100
11,200
10,300
9,900
9,500
8,900
8,000
8,000
7,500
10,500
9,500
12,600
10,500
13,200
13,400
11,200
8,200
6,300
5,200
5,184
8,158
8,338
7,107
5,625
4,295
2,614
1,888
1,721
1,721
2,588
2,087
1,985
1,921
1,887
1,938
1,963
1,968
2,758
2,662
8,596
6,695
6,204
5,701
7,806
7,926
7,581
7,628
7,997
7,997
5,217
5,537
4,857
4,857
1,387
841
590
558
590
558
1,384
924
687
329
185
137
228
371
129
129
125
88
226
118
154
62
147
103
52
226
147
1,425
132
49
54
37
362
160
25
238
42
256,520
254,368
257,333
255,014
26,536
25,399
25,539
25,707
482
396
295
1,063
917
6
5,661
39,567
35,798
32,169
27,439
24,170
21,071
16,736
20,086
18,144
16,148
14,109
14,10916,14818,14420,08616,73621,07124,17027,43932,16935,79839,5675,66169171,06329539648225,70725,53925,39926,536255,014257,333254,368256,52042238251603623754491321,4251472265210314762154118226881251291293712281371853296879241,3845585905585908411,3874,8574,8575,5375,2177,9977,9977,6287,5817,9267,8065,7016,2046,6958,5962,6622,7581,9681,9631,9381,8871,9211,9852,0872,5881,7211,7211,8882,6144,2955,6257,1078,3388,1585,1845,2006,3008,20011,20013,40013,20010,50012,6009,50010,5007,5008,0008,0008,9009,5009,90010,30011,20011,10011,20012,1003,7003,1003,1003,5003,5004,9004,9004,8004,8004,5004,8005,3005,0004,9005,0004,8005,1004,9004,4004,3004,20003,5000003,3000003,3000003,2000
   > Total Current Assets 
0
2,800
0
0
0
2,900
0
0
0
2,800
0
0
0
3,200
0
4,100
4,000
4,300
4,700
5,000
4,600
4,900
4,800
4,800
5,200
4,600
4,300
4,600
4,500
4,700
4,700
3,300
3,300
2,900
2,900
2,800
3,300
3,100
2,900
3,100
3,100
2,800
2,700
2,600
2,000
2,100
1,900
5,500
4,700
5,200
3,400
6,400
6,900
5,400
4,700
4,100
3,200
3,225
6,294
6,555
5,359
3,913
2,677
1,467
908
706
706
1,604
1,154
1,051
1,050
931
1,024
1,057
1,056
1,814
1,650
7,540
5,724
5,177
4,550
5,441
5,601
5,208
5,281
5,701
5,701
2,955
3,177
2,627
2,627
820
335
275
257
275
257
1,293
840
610
259
137
96
194
343
104
104
109
73
202
94
131
40
125
77
32
202
125
1,420
127
44
49
32
357
156
21
235
39
2,732
576
2,870
1,096
1,247
90
78
286
337
274
188
971
833
6
5,661
39,567
35,798
32,169
27,193
23,947
20,872
16,562
19,937
18,021
16,052
14,056
14,05616,05218,02119,93716,56220,87223,94727,19332,16935,79839,5675,661683397118827433728678901,2471,0962,8705762,73239235211563573249441271,4201252023277125401319420273109104104343194961372596108401,2932572752572753358202,6272,6273,1772,9555,7015,7015,2815,2085,6015,4414,5505,1775,7247,5401,6501,8141,0561,0571,0249311,0501,0511,1541,6047067069081,4672,6773,9135,3596,5556,2943,2253,2004,1004,7005,4006,9006,4003,4005,2004,7005,5001,9002,1002,0002,6002,7002,8003,1003,1002,9003,1003,3002,8002,9002,9003,3003,3004,7004,7004,5004,6004,3004,6005,2004,8004,8004,9004,6005,0004,7004,3004,0004,10003,2000002,8000002,9000002,8000
       Cash And Cash Equivalents 
0
1,800
0
0
0
2,400
0
0
0
2,400
0
0
0
2,600
0
400
500
3,600
300
400
400
4,700
300
500
100
300
300
200
100
300
300
900
700
800
1,200
1,100
800
900
700
900
1,000
700
900
1,100
100
400
300
4,200
2,800
1,300
400
3,300
4,100
2,600
1,500
1,100
200
789
4,205
4,564
3,203
2,059
1,041
462
258
221
221
934
486
424
371
172
238
372
308
1,115
786
4,687
4,981
4,452
3,845
614
719
461
677
1,208
1,208
1,208
1,591
1,140
1,140
232
31
22
0
22
44
1,293
840
571
181
54
1
89
0
92
92
5
61
123
0
11
0
43
4
1
123
43
1,418
125
42
47
30
355
154
19
235
39
2,732
576
2,870
1,096
1,232
60
51
264
313
28
5
851
350
5
5,297
39,505
9,682
8,968
7,286
5,358
2,465
5,672
2,045
2,767
2,648
1,079
1,0792,6482,7672,0455,6722,4655,3587,2868,9689,68239,5055,297535085152831326451601,2321,0962,8705762,73239235191543553047421251,418431231443011012361592920891541815718401,2934422022312321,1401,1401,5911,2081,2081,2086774617196143,8454,4524,9814,6877861,1153083722381723714244869342212212584621,0412,0593,2034,5644,2057892001,1001,5002,6004,1003,3004001,3002,8004,2003004001001,1009007001,0009007009008001,1001,2008007009003003001002003003001005003004,7004004003003,60050040002,6000002,4000002,4000001,8000
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,200
2,500
0
3,400
3,600
4,000
0
4,300
4,000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
26,031
23,011
19,454
18,367
18,319
10,836
17,854
15,206
13,366
12,893
12,89313,36615,20617,85410,83618,31918,36719,45423,01126,0310000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000004,0004,30004,0003,6003,40002,5002,200000000000000000
       Net Receivables 
0
400
0
0
0
100
0
0
0
100
0
0
0
200
0
1,000
600
400
700
800
0
0
0
200
700
100
0
500
600
800
800
0
900
600
100
1,400
1,700
1,200
1,200
1,200
1,100
800
700
600
1,000
900
1,000
600
900
2,000
1,100
1,300
900
1,000
1,100
1,500
1,400
1,072
760
665
736
502
379
354
158
149
149
136
196
188
254
220
265
251
291
198
370
2,479
342
272
297
865
1,002
930
894
732
732
1,126
832
830
830
267
226
250
254
250
254
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
40
30
5
0
40
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000000000000000004005304000000000000000002542502542502262678308308321,1267327328949301,0028652972723422,4793701982912512652202541881961361491491583543795027366657601,0721,4001,5001,1001,0009001,3001,1002,0009006001,0009001,0006007008001,1001,2001,2001,2001,7001,400100600900080080060050001007002000008007004006001,00002000001000001000004000
       Other Current Assets 
0
200
0
0
0
0
0
0
0
100
0
0
0
200
0
400
200
100
100
100
100
100
100
0
4,300
4,100
3,900
3,800
3,700
3,500
3,500
2,100
1,400
1,300
1,400
100
400
300
300
300
200
300
200
200
300
200
100
200
300
100
0
-100
100
200
500
100
200
37
48
81
123
81
160
130
90
44
44
212
168
138
111
217
167
139
67
46
145
128
102
156
119
3,312
3,240
3,194
3,156
140
3,200
91
108
137
137
86
15
0
0
250
250
0
0
39
78
83
95
105
343
0
12
12
12
20
0
0
0
0
1
0
20
1
2
2
2
2
2
2
2
2
0
0
0
0
0
0
15
30
27
22
24
246
183
120
483
0
364
62
85
190
453
222
88
54
38
48
38
84
843848385488222453190856236404831201832462422273015000000222222221200100002012121203431059583783900250250001586137137108913,2001403,1563,1943,2403,312119156102128145466713916721711113816821244449013016081123814837200100500200100-10001003002001002003002002003002003003003004001001,4001,3001,4002,1003,5003,5003,7003,8003,9004,1004,3000100100100100100100200400020000010000000002000
   > Long-term Assets 
0
400
0
0
0
400
0
0
0
500
0
0
0
300
0
100
300
100
200
100
200
100
100
200
100
200
200
200
300
200
200
200
200
200
200
900
8,800
8,100
8,200
8,100
7,200
7,100
6,800
6,300
6,000
5,900
5,600
5,000
4,800
7,400
7,100
6,800
6,500
5,800
3,500
2,200
2,000
1,959
1,864
1,783
1,748
1,712
1,618
1,147
980
0
1,015
984
933
934
871
956
914
906
912
944
1,012
1,056
971
1,027
1,151
2,365
2,325
2,373
2,347
2,296
2,296
2,262
2,360
0
2,230
567
506
315
301
315
301
91
84
77
70
48
41
34
28
25
25
16
15
24
24
23
22
22
26
20
24
22
5
5
5
5
5
5
4
4
3
3
253,788
253,792
254,463
253,918
25,289
25,309
25,461
25,421
145
122
107
92
84
0
0
0
0
0
246
223
199
174
149
123
96
53
539612314917419922324600000849210712214525,42125,46125,30925,289253,918254,463253,792253,78833445555552224202622222324241516252528344148707784913013153013155065672,23002,3602,2622,2962,2962,3472,3732,3252,3651,1511,0279711,0561,0129449129069149568719349339841,01509801,1471,6181,7121,7481,7831,8641,9592,0002,2003,5005,8006,5006,8007,1007,4004,8005,0005,6005,9006,0006,3006,8007,1007,2008,1008,2008,1008,80090020020020020020020030020020020010020010010020010020010030010003000005000004000004000
       Property Plant Equipment 
0
100
0
0
0
100
0
0
0
100
0
0
0
200
0
100
100
100
200
100
200
100
100
100
100
200
200
200
200
200
200
200
200
200
200
200
2,900
1,300
1,300
1,300
1,100
1,100
1,000
900
1,400
1,300
1,400
1,300
1,200
4,000
3,800
3,600
3,500
2,800
900
900
900
808
738
689
691
651
588
165
114
102
102
73
59
62
59
49
37
42
36
42
43
61
59
57
68
243
232
259
252
244
244
207
190
169
169
46
30
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
6
5
5
5
5
5
5
4
4
3
3
2
6
7
6
5
35
187
147
133
110
95
80
72
0
0
0
0
0
237
214
190
165
140
114
87
53
538711414016519021423700000728095110133147187355676233445555556000000000000000000000000304616916919020724424425225923224368575961434236423749596259731021021141655886516916897388089009009002,8003,5003,6003,8004,0001,2001,3001,4001,3001,4009001,0001,1001,1001,3001,3001,3002,90020020020020020020020020020020020010010010010020010020010010010002000001000001000001000
       Goodwill 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,291
1,291
1,299
1,299
1,199
1,199
1,291
1,430
1,331
1,331
7
7
7
7
7
7
7
7
7
7
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
253,777
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000000253,77700000000000000000000000000077777777771,3311,3311,4301,2911,1991,1991,2991,2991,2911,291000000000000000000000000000000000000000000000000000000000000000000000000000000000
       Intangible Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
681
0
0
0
426
426
524
544
594
615
907
877
733
816
902
969
995
912
970
995
831
802
815
796
761
761
764
740
561
561
514
469
308
294
308
294
84
77
70
63
48
41
34
28
25
25
16
15
24
24
23
22
22
21
20
24
22
0
0
0
0
0
0
0
0
0
0
253,777
253,777
253,777
253,777
25,263
25,262
25,262
25,262
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000025,26225,26225,26225,263253,777253,777253,777253,77700000000002224202122222324241516252528344148637077842943082943084695145615617407647617617968158028319959709129959699028167338779076155945445244264260006810000000000000000000000000000000000000000000000000000000000000
       Other Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,126
1,094
1,057
1,061
1,030
982
866
913
888
911
874
872
812
907
877
864
876
902
969
875
1,043
970
1,083
2,122
2,093
2,114
2,095
2,052
2,027
2,055
2,170
2,061
2,039
521
476
315
301
287
274
91
84
77
70
48
41
34
28
25
22
16
15
24
24
23
22
22
26
20
20
0
0
0
0
0
0
0
0
0
0
0
253,786
253,786
679
135
21
12
12
12
12
12
12
12
12
0
0
0
0
0
9
0
9
0
0
0
0
0
0000090900000121212121212121221135679253,786253,7860000000000020202622222324241516222528344148707784912742873013154765212,0392,0612,1702,0552,0272,0522,0952,1142,0932,1221,0839701,0438759699028768648779078128728749118889138669821,0301,0611,0571,0941,1260000000000000000000000000000000000000000000000000000000000
> Total Liabilities 
0
100
0
0
0
500
0
0
0
200
0
0
0
300
0
500
500
500
600
500
100
200
100
200
600
200
-200
200
300
600
600
200
600
300
500
1,300
4,500
4,500
4,700
4,500
4,200
5,600
6,000
2,300
2,900
3,500
4,400
2,900
3,300
5,800
5,600
4,400
4,200
4,000
2,200
2,100
2,100
2,495
1,796
1,670
1,578
1,552
1,360
1,474
1,104
1,188
1,188
919
700
767
847
1,071
1,035
1,093
1,106
3,038
2,963
2,680
949
725
539
4,268
4,933
4,983
5,331
7,802
7,802
4,280
4,127
3,228
3,228
4,154
4,405
4,270
4,524
4,270
4,524
7,108
8,039
6,182
5,594
5,654
7,161
5,798
5,277
5,230
5,230
6,559
6,326
6,562
5,407
5,758
6,031
6,481
6,808
7,017
6,562
6,481
51,358
23,032
24,598
61,888
20,256
16,194
17,366
18,949
18,348
20,126
2,802
2,679
5,076
8,952
13,223
14,029
15,523
16,731
18,768
19,706
21,150
28,562
30,694
6
35,094
3,276
3,922
10,259
9,650
8,730
5,117
5,002
7,033
6,381
6,143
6,633
6,6336,1436,3817,0335,0025,1178,7309,65010,2593,9223,27635,094630,69428,56221,15019,70618,76816,73115,52314,02913,2238,9525,0762,6792,80220,12618,34818,94917,36616,19420,25661,88824,59823,03251,3586,4816,5627,0176,8086,4816,0315,7585,4076,5626,3266,5595,2305,2305,2775,7987,1615,6545,5946,1828,0397,1084,5244,2704,5244,2704,4054,1543,2283,2284,1274,2807,8027,8025,3314,9834,9334,2685397259492,6802,9633,0381,1061,0931,0351,0718477677009191,1881,1881,1041,4741,3601,5521,5781,6701,7962,4952,1002,1002,2004,0004,2004,4005,6005,8003,3002,9004,4003,5002,9002,3006,0005,6004,2004,5004,7004,5004,5001,300500300600200600600300200-20020060020010020010050060050050050003000002000005000001000
   > Total Current Liabilities 
0
100
0
0
0
600
0
0
0
200
0
0
0
300
0
500
500
500
600
500
100
200
100
200
600
200
100
200
300
600
600
200
700
300
500
1,300
3,900
4,100
4,400
4,100
3,800
4,200
4,700
2,300
2,900
3,500
4,400
2,900
3,200
4,300
3,900
2,700
2,500
2,400
2,000
1,900
2,000
2,301
1,608
1,502
1,418
1,402
1,217
1,318
1,103
1,186
1,186
919
700
767
847
1,071
1,035
1,093
1,106
3,038
2,963
2,680
949
725
539
4,227
4,892
4,942
5,290
7,653
7,653
3,797
3,474
3,203
3,203
4,154
4,405
4,270
4,524
4,270
4,524
6,859
7,543
5,778
5,190
5,654
7,161
5,798
5,277
5,230
5,230
6,559
6,326
6,562
5,407
5,758
6,031
6,384
6,680
6,861
6,562
6,384
50,509
21,581
22,308
61,174
19,703
15,666
16,966
18,949
18,348
20,126
2,802
2,679
5,076
8,952
13,223
14,029
15,523
16,731
18,768
19,706
21,150
28,562
30,694
35
35,094
3,276
3,922
10,259
9,503
8,610
5,025
4,938
4,076
4,843
5,090
6,633
6,6335,0904,8434,0764,9385,0258,6109,50310,2593,9223,27635,0943530,69428,56221,15019,70618,76816,73115,52314,02913,2238,9525,0762,6792,80220,12618,34818,94916,96615,66619,70361,17422,30821,58150,5096,3846,5626,8616,6806,3846,0315,7585,4076,5626,3266,5595,2305,2305,2775,7987,1615,6545,1905,7787,5436,8594,5244,2704,5244,2704,4054,1543,2033,2033,4743,7977,6537,6535,2904,9424,8924,2275397259492,6802,9633,0381,1061,0931,0351,0718477677009191,1861,1861,1031,3181,2171,4021,4181,5021,6082,3012,0001,9002,0002,4002,5002,7003,9004,3003,2002,9004,4003,5002,9002,3004,7004,2003,8004,1004,4004,1003,9001,30050030070020060060030020010020060020010020010050060050050050003000002000006000001000
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
500
800
1,400
800
1,700
1,900
1,900
500
400
1,300
1,500
1,200
1,200
1,500
1,500
1,000
800
800
800
800
700
775
542
541
541
259
259
295
284
92
252
181
166
160
160
160
160
160
279
1,621
1,764
1,360
160
0
0
3,060
3,660
3,660
3,545
3,060
3,060
0
0
0
966
1,074
2,143
2,123
2,123
2,148
2,158
2,125
2,106
1,932
1,769
2,164
2,038
2,094
198
1,770
2,061
2,205
2,680
1,088
1,166
1,409
1,511
1,614
1,696
1,742
1,880
2,491
2,909
2,951
3,808
9,033
10,026
10,073
10,891
12,413
11,792
12,419
31
31
2,963
6,887
10,628
10,804
11,489
12,348
13,308
13,358
13,393
21,965
23,113
26
26,334
31
31
31
100
103
106
110
116
120
92
58
589212011611010610310031313126,3342623,11321,96513,39313,35813,30812,34811,48910,80410,6286,8872,963313112,41911,79212,41310,89110,07310,0269,0333,8082,9512,9092,4911,8801,7421,6961,6141,5111,4091,1661,0882,6802,2052,0611,7701982,0942,0382,1641,7691,9322,1062,1252,1582,1482,1232,1232,1431,0749660003,0603,0603,5453,6603,6603,060001601,3601,7641,621279160160160160160166181252922842952592595415415427757008008008008001,0001,5001,5001,2001,2001,5001,3004005001,9001,9001,7008001,400800500000000000000000000000000000000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
12,413
11,792
12,419
31
31
2,963
6,887
0
0
11,328
12,201
13,174
13,238
13,288
21,875
23,031
26,334
31
31
31
31
0
0
0
0
0
0
0
0
000000003131313126,33423,03121,87513,28813,23813,17412,20111,328006,8872,963313112,41911,79212,41300000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
       Accounts payable 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
500
500
0
600
500
100
0
100
200
0
0
0
0
0
0
0
0
0
300
400
700
1,300
1,600
2,100
1,600
1,200
1,200
1,700
900
1,600
1,400
2,100
800
1,300
1,600
1,300
900
900
700
600
600
800
1,131
462
479
561
628
517
699
622
589
589
486
305
321
392
575
436
609
539
636
536
491
396
399
334
699
858
907
948
763
763
955
977
1,034
1,034
1,343
959
919
967
919
967
925
779
810
624
625
856
772
974
806
806
813
858
878
883
904
935
940
935
925
878
940
256
431
968
893
1,538
1,574
1,814
2,100
2,061
2,347
2,714
2,546
1,830
1,887
2,251
1,762
1,898
1,710
1,720
1,940
2,370
2,001
2,171
2,243
2,243
1,497
2,802
8,189
8,113
7,263
3,325
3,140
3,131
3,501
3,970
4,328
4,3283,9703,5013,1313,1403,3257,2638,1138,1892,8021,4972,2432,2432,1712,0012,3701,9401,7201,7101,8981,7622,2511,8871,8302,5462,7142,3472,0612,1001,8141,5741,5388939684312569408789259359409359048838788588138068069747728566256248107799259679199679199591,3431,0341,0349779557637639489078586993343993964915366365396094365753923213054865895896226995176285614794621,1318006006007009009001,3001,6001,3008002,1001,4001,6009001,7001,2001,2001,6002,1001,6001,30070040030000000000020010001005006000500500000000000000000
       Other Current Liabilities 
0
100
0
0
0
600
0
0
0
200
0
0
0
300
0
0
0
500
0
0
0
200
0
0
600
200
100
200
300
600
600
200
700
0
100
600
2,100
1,700
900
1,700
900
1,100
1,100
900
900
800
800
900
700
1,200
1,100
800
800
900
600
500
500
395
604
482
316
515
601
324
197
345
302
252
223
273
282
323
71
324
288
781
663
829
393
326
205
468
374
375
115
3,830
2,314
2,842
2,497
1,372
2,169
668
164
1,203
1,399
174
229
2,405
3,153
1,450
1,081
1,012
984
980
1,934
2,363
158
514
514
3,804
2,599
2,687
2,826
2,953
3,148
3,268
1,378
109
39,702
13,299
11,345
44,531
4,795
492
184
417
528
964
57
102
283
178
344
1,463
161
2,673
3,740
4,408
5,387
4,596
5,410
383
383
842
340
138
1,290
1,244
1,594
1,688
829
1,222
1,028
2,247
2,2471,0281,2228291,6881,5941,2441,2901383408423833835,4104,5965,3874,4083,7402,6731611,463344178283102579645284171844924,79544,53111,34513,29939,7021091,3783,2683,1482,9532,8262,6872,5993,8045145141582,3631,9349809841,0121,0811,4503,1532,4052291741,3991,2031646682,1691,3722,4972,8422,3143,830115375374468205326393829663781288324713232822732232523023451973246015153164826043955005006009008008001,1001,2007009008008009009001,1001,1009001,7009001,7002,1006001000700200600600300200100200600002000005000003000002000006000001000
   > Long-term Liabilities 
0
0
0
0
0
-100
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-100
0
0
0
0
0
-100
0
0
0
600
400
300
400
400
1,400
1,300
100
0
0
0
0
100
1,500
1,700
1,700
1,700
1,600
200
200
100
194
188
168
160
150
143
156
1
0
2
0
0
0
0
0
0
0
0
0
0
0
0
0
0
41
41
41
41
149
149
483
653
0
25
0
0
0
0
0
0
249
496
404
404
0
0
0
0
0
0
0
0
0
0
0
0
97
128
156
306
97
849
1,451
2,290
714
553
528
400
0
0
0
-1
714
0
0
0
0
0
0
0
0
0
0
0
0
-29
0
0
8,220
147
120
92
64
2,957
1,538
1,053
0
01,0531,5382,95764921201478,22000-29000000000000714-10004005285537142,2901,451849973061561289700000000000040440449624900000025065348314914941414141000000000000002011561431501601681881941002002001,6001,7001,7001,7001,50010000001001,3001,400400400300400600000-10000000-10000000000000000000000-10000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
670
126
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000001266700000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
> Total Stockholder Equity
0
3,100
0
0
0
2,800
0
0
0
3,100
0
0
0
3,200
0
3,700
3,700
3,900
4,300
4,600
4,700
4,800
4,800
4,700
4,700
4,600
4,500
4,600
4,500
4,300
4,300
3,300
2,900
2,800
2,600
2,400
7,600
6,700
6,400
6,700
6,100
4,300
3,500
6,600
5,100
4,500
3,100
7,600
6,200
6,800
4,900
8,800
9,200
7,200
6,000
4,200
3,100
2,689
6,362
6,668
5,529
4,073
2,935
1,140
784
533
533
1,669
1,387
1,218
1,074
816
903
870
862
-280
-301
5,916
5,746
5,479
5,162
2,934
2,339
1,908
1,519
0
-575
32
442
763
763
-2,767
-3,564
0
0
-3,680
-3,966
-5,724
-7,115
-5,495
-5,265
-5,469
-7,024
-5,570
-4,906
0
-5,101
-6,421
-6,111
0
0
0
0
0
0
0
-6,246
-6,181
-49,764
-22,731
-24,380
-61,665
-20,050
-15,663
-17,037
-18,755
-17,941
-19,915
253,887
251,858
252,426
246,231
13,482
11,539
10,185
9,145
-18,117
-19,141
-20,686
-27,330
-29,608
-29,264
-29,264
36,460
32,045
21,910
17,789
15,440
15,954
11,734
13,053
11,763
10,005
7,476
7,47610,00511,76313,05311,73415,95415,44017,78921,91032,04536,460-29,264-29,264-29,608-27,330-20,686-19,141-18,1179,14510,18511,53913,482246,231252,426251,858253,887-19,915-17,941-18,755-17,037-15,663-20,050-61,665-24,380-22,731-49,764-6,181-6,2460000000-6,111-6,421-5,1010-4,906-5,570-7,024-5,469-5,265-5,495-7,115-5,724-3,966-3,68000-3,564-2,76776376344232-57501,5191,9082,3392,9345,1625,4795,7465,916-301-2808628709038161,0741,2181,3871,6695335337841,1402,9354,0735,5296,6686,3622,6893,1004,2006,0007,2009,2008,8004,9006,8006,2007,6003,1004,5005,1006,6003,5004,3006,1006,7006,4006,7007,6002,4002,6002,8002,9003,3004,3004,3004,5004,6004,5004,6004,7004,7004,8004,8004,7004,6004,3003,9003,7003,70003,2000003,1000002,8000003,1000
   Common Stock
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
15,400
15,400
0
15,400
15,400
15,400
0
15,400
15,400
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
8
9
9
9
9
9
9
9
10
10
10
10
10
10
25
26
26
26
27
27
41
42
42
42
43
43
43
43
45
45
45
47
47
47
47
47
47
47
47
47
67
80
119
144
149
170
209
239
269
269
364
457
501
573
573
573
574
574
574
501
574
596
600
600
2
22
26
28
31
123
0
50
50
50
50
50
51
51
53
67
70
71
75
78
52
52
10,744
3,446
1,145
32
31
33
33
37
41
42
1
1424137333331321,1453,44610,7445252787571706753515150505050500123312826222600600596574501574574574573573573501457364269269239209170149144119806747474747474747474745454543434343424242412727262626251010101010109999999800000000000000000000000000000000015,40015,400015,40015,40015,400015,40015,400000000000000000
   Retained Earnings Total Equity000000000-635,393-629,940-595,6280000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
   Accumulated Other Comprehensive Income 
0
-200
0
0
0
-300
0
0
0
-200
0
0
0
-300
0
0
0
-300
0
0
0
-200
0
0
-300
-200
-200
-200
-200
-200
-200
-200
-200
-200
-200
-200
-200
-400
-400
-400
-400
-800
-800
-800
-800
-2,300
-2,300
-2,300
-2,300
-2,800
-2,800
-2,800
-2,800
-1,000
-1,000
-300
-300
-335
-361
-355
-375
2,487
1,618
1,258
1,268
-706
1,242
1,575
1,567
1,564
1,569
7
-186
-32
503
502
504
3,906
3,914
3,914
3,914
-417
-417
-417
-417
-852
-417
-417
-417
-927
-417
-417
-417
0
0
0
-47
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-1
-1
-1-10000000000000000000000000000000000000000000000000000000-47000-417-417-417-927-417-417-417-852-417-417-417-4173,9143,9143,9143,906504502503-32-18671,5691,5641,5671,5751,242-7061,2681,2581,6182,487-375-355-361-335-300-300-1,000-1,000-2,800-2,800-2,800-2,800-2,300-2,300-2,300-2,300-800-800-800-800-400-400-400-400-200-200-200-200-200-200-200-200-200-200-200-200-30000-200000-300000-300000-200000-300000-2000
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
566,309
655,655
663,991
0
0
0
0
0
0
0
0
0
000000000663,991655,655566,3090000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
   Treasury Stock0000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
15,500
0
0
0
15,700
0
0
0
15,600
0
0
0
15,700
0
-100
-100
18,600
0
-100
0
15,600
-100
-100
15,600
15,500
15,600
15,500
15,600
15,600
15,600
15,600
15,600
15,600
15,600
15,600
25,200
25,200
25,700
25,200
31,700
32,100
32,900
37,500
37,400
39,800
39,800
45,600
45,600
47,800
47,700
52,800
55,300
53,500
53,500
52,800
52,700
52,756
57,422
58,823
58,823
55,956
56,835
57,156
57,155
0
57,155
58,302
58,328
58,327
58,327
59,909
60,332
60,365
60,415
60,466
60,496
64,114
64,304
64,337
64,342
68,686
68,781
68,929
69,193
0
70,115
70,411
70,939
0
70,980
71,077
71,077
0
0
71,126
71,173
71,309
72,003
73,185
74,023
74,474
74,821
76,898
77,509
0
78,422
80,017
81,634
0
0
0
0
0
0
0
82,216
82,709
83,109
83,278
83,321
84,012
99,659
102,498
104,752
105,860
108,897
109,876
515,705
519,702
531,963
534,849
537,883
540,171
543,327
545,073
547,675
548,118
548,280
550,389
550,984
0
566,309
655,655
663,991
674,348
676,780
677,411
684,804
686,168
687,710
688,408
689,066
689,540
689,540689,066688,408687,710686,168684,804677,411676,780674,348663,991655,655566,3090550,984550,389548,280548,118547,675545,073543,327540,171537,883534,849531,963519,702515,705109,876108,897105,860104,752102,49899,65984,01283,32183,27883,10982,70982,216000000081,63480,01778,422077,50976,89874,82174,47474,02373,18572,00371,30971,17371,1260071,07771,07770,980070,93970,41170,115069,19368,92968,78168,68664,34264,33764,30464,11460,49660,46660,41560,36560,33259,90958,32758,32758,32858,30257,155057,15557,15656,83555,95658,82358,82357,42252,75652,70052,80053,50053,50055,30052,80047,70047,80045,60045,60039,80039,80037,40037,50032,90032,10031,70025,20025,70025,20025,20015,60015,60015,60015,60015,60015,60015,60015,60015,50015,60015,50015,600-100-10015,6000-100018,600-100-100015,70000015,60000015,70000015,5000



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue0
Cost of Revenue-0
Gross Profit00
 
Operating Income (+$)
Gross Profit0
Operating Expense-13,576
Operating Income-13,576-13,576
 
Operating Expense (+$)
Research Development6,466
Selling General Administrative8,235
Selling And Marketing Expenses0
Operating Expense13,57614,701
 
Net Interest Income (+$)
Interest Income741
Interest Expense-213
Other Finance Cost-8
Net Interest Income520
 
Pretax Income (+$)
Operating Income-13,576
Net Interest Income520
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-7,597-19,555
EBIT - interestExpense = -213
-7,597
-7,384
Interest Expense213
Earnings Before Interest and Taxes (EBIT)0-7,384
Earnings Before Interest and Taxes (EBITDA)-13,576
 
After tax Income (+$)
Income Before Tax-7,597
Tax Provision-0
Net Income From Continuing Ops-10,219-7,597
Net Income-7,597
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses13,576
Total Other Income/Expenses Net5,979-520
 

Technical Analysis of GT Biopharma Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of GT Biopharma Inc. The general trend of GT Biopharma Inc is BEARISH with 100.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine GT Biopharma Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-100.0%) Bearish trend (100.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of GT Biopharma Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 3.81 < 5.14 < 5.21.

The bearish price targets are: 3.52.

Tweet this
GT Biopharma Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of GT Biopharma Inc. The current mas is .

The long score for the Moving Averages is 0/14.
The longshort score for the Moving Averages is -14/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

GT Biopharma Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of GT Biopharma Inc. The current macd is -0.21006904.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the GT Biopharma Inc price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for GT Biopharma Inc. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the GT Biopharma Inc price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
GT Biopharma Inc Daily Moving Average Convergence/Divergence (MACD) ChartGT Biopharma Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of GT Biopharma Inc. The current adx is 11.40.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -2/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell GT Biopharma Inc shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bearish trend could be forming. -1
GT Biopharma Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of GT Biopharma Inc. The current sar is 4.24546007.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
GT Biopharma Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of GT Biopharma Inc. The current rsi is 39.18. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -3/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
GT Biopharma Inc Daily Relative Strength Index (RSI) ChartGT Biopharma Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of GT Biopharma Inc. The current phase is Oversold in bear market.

The long score for the Stochastic Oscillator is 1/6.
The longshort score for the Stochastic Oscillator is -4/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the GT Biopharma Inc price going down in the near term. -2
  • Trending up: The STOCH %K is trending up. +1
GT Biopharma Inc Daily Stochastic Oscillator ChartGT Biopharma Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of GT Biopharma Inc. The current cci is -106.8855143.

The long score for the Commodity Channel Index (CCI) is 0/1.
The longshort score for the Commodity Channel Index (CCI) is -1/(-1 +1).

  • CCI < -100: The CCI is below -100, it indicates that the price is significantly below its average, suggesting a potential oversold condition. -1
GT Biopharma Inc Daily Commodity Channel Index (CCI) ChartGT Biopharma Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of GT Biopharma Inc. The current cmo is -26.70810835.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
GT Biopharma Inc Daily Chande Momentum Oscillator (CMO) ChartGT Biopharma Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of GT Biopharma Inc. The current willr is -89.56521739.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
GT Biopharma Inc Daily Williams %R ChartGT Biopharma Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of GT Biopharma Inc.

GT Biopharma Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of GT Biopharma Inc. The current atr is 0.31153243.

GT Biopharma Inc Daily Average True Range (ATR) ChartGT Biopharma Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of GT Biopharma Inc. The current obv is -62,741.

GT Biopharma Inc Daily On-Balance Volume (OBV) ChartGT Biopharma Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of GT Biopharma Inc. The current mfi is 34.09.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
GT Biopharma Inc Daily Money Flow Index (MFI) ChartGT Biopharma Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for GT Biopharma Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-12-01STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-04STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-05MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2023-12-06STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-07CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-11WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-12STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-13CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-15CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-18WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-19STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-21STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-22STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-28STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-29STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-03STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-04STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-08MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-10DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-12STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-01-16DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-17STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-01-18WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-22STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-23STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-24STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-26CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-29STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-30STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-31CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-01DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-05STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-08STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-12STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-02-13BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-14STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-16RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2024-02-21STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-23STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-26MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-27SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-02-28MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-03-04CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-05STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-07STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-11DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-12MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-03-13STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-03-15DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-03-18SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-03-20WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-21CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-22DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-03-25CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-26DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-03-28DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-01DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-03DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-04DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-08SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-09MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-10STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-16STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-18STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-23STOCH LONG EXITThe %K line crosses below the %D line.

6.3. Candlestick Patterns

GT Biopharma Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of GT Biopharma Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5039.178
Ma 20Greater thanMa 504.032
Ma 50Greater thanMa 1004.201
Ma 100Greater thanMa 2005.468
OpenGreater thanClose3.650
Total0/5 (0.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of GT Biopharma Inc with someone you think should read this too:
  • Are you bullish or bearish on GT Biopharma Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about GT Biopharma Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about GT Biopharma Inc

I send you an email if I find something interesting about GT Biopharma Inc.


Comments

How you think about this?

Leave a comment

Stay informed about GT Biopharma Inc.

Receive notifications about GT Biopharma Inc in your mailbox!